APOE and Cognitive impairment: So far, LIBRA has been shown to explain variance in cognitive functioning and dementia risk in various population‐ and patient‐based prospective cohort studies.7, 8, 9, 10, 11 Yet, more research is needed into the predictive validity of LIBRA: (a) for other outcome measurements such as mild cognitive impairment (MCI), (b) in an aging cohort (followed from midlife to late‐life), (c) in long‐term cohort studies where follow‐up may be decades later, and (d) in interaction with genetic risk (eg, apolipoprotein E [APOE] ε4 genotype).